<DOC>
	<DOCNO>NCT00105989</DOCNO>
	<brief_summary>The purpose study assess efficacy safety duloxetine compare placebo prevention depressive recurrence among patient recurrent major depressive disorder .</brief_summary>
	<brief_title>Duloxetine Versus Placebo Prevention Recurrence Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Patient must least 18 year old . Patient must diagnose depression previous episode depression . Patient must sign informed consent . Female pregnant breastfeeding . History bipolar disorder , schizophrenia , psychotic disorder . Suffer serious medical illness ( depression ) abnormal laboratory result would require change medication , intervention , hospitalization . Have treat medication call monoamine oxidase inhibitor ( MAOI ) within 14 day start study , potential need use MAOI within 5 day finish study . Have take antidepressant call fluoxetine within 30 day start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>